Naltrexone, formulated as an extended-release injectable suspension known as Vivitrol, requires administration by a licensed healthcare professional. This typically includes physicians (MD and DO), physician assistants (PAs), and nurse practitioners (NPs) who have received the necessary training and are authorized to prescribe medications within their respective jurisdictions. Regulations regarding prescribing authority can vary by state and locality. Specific requirements for prescribing extended-release naltrexone should be confirmed with the relevant licensing boards.
Access to qualified prescribers is crucial for individuals seeking medication-assisted treatment (MAT) for opioid or alcohol dependence. Administering extended-release naltrexone reduces the risk of relapse by blocking opioid receptors, thus diminishing cravings and the euphoric effects of these substances. This approach, when combined with counseling and psychosocial support, can significantly improve treatment outcomes and support long-term recovery. The development of long-acting formulations like this injectable has enhanced adherence to treatment regimens compared to oral naltrexone, offering a valuable tool in combating addiction.